Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466070 | 0.85 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL2112935 | 0.84 | HDAC3 (0.54) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL754623 | 0.83 | HDAC1 (0.43) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL16678597 | 0.82 | KMT2A (0.45) | L3MBTL1MEN1KMT2ARECQLLMNA | |
| SCHEMBL16678636 | 0.82 | KMT2A (0.45) | L3MBTL1MEN1KMT2ARECQLLMNA | |
| SCHEMBL16678595 | 0.82 | KMT2A (0.45) | L3MBTL1MEN1KMT2ARECQLLMNA | |
| SCHEMBL1848202 | 0.81 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL17595115 | 0.81 | BACE1 (0.49) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL9823156 | 0.81 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL3328177 | 0.81 | HDAC3 (0.54) | HDAC1HDAC3HDAC2NCOR2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908759-B1 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2012-03-21 | — | — | EP | disclosed |
| EP-1908760-B1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| EP-1911757-B1 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | BIAL - PORTELA & CA S.A. (PT) | 2010-11-11 | — | — | US | disclosed |
| EP-2111262-A2 | 1,3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-10-28 | — | — | EP | disclosed |
| EP-1408038-B1 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | BIAL PORTELA & CA SA (PT) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008085074-A2 | 1, 3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA., S.A. (PT) | 2008-07-17 | — | — | WO | disclosed |
| CN-100393715-C | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | PORTELA & CA SA (PT) | 2008-06-11 | — | — | CN | disclosed |
| EP-1914233-A1 | Peripherally-selective inhibitors of dopamine-b-hydroxylase and method of their preparation | Portela & Ca., S.A. (PT) | 2008-04-23 | — | — | EP | disclosed |
| EP-1911757-A2 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | Portela & Ca., S.A. (PT) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908759-A2 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| CN-1726211-A | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | PORTELA & CA SA (PT) | 2006-01-25 | — | — | CN | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | HDAC1 1502/4885HDAC3 1569/4885HDAC2 2315/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | HDAC1 1414/4885HDAC3 1359/4885HDAC2 1892/4885 |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | HTR1F, HTR1D, ADRB3 | HDAC1 1160/4885HDAC3 375/4885HDAC2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.